Loading...
DOCUMENTS
20
NOTICES
33
MOTS CLES
COLON-CANCER
Kidney diseases
Primary sclerosing cholangitis
Patients experience
MARKER
Bactéries
Parvimonas micra
Microbiota
Biomarker
Colonic epithelial primary cells
MALT
Screening
Epigénétiques
Disease progression
Clinical trial
Crohn’s disease
Maintenance therapy
Safety
Rituximab
CARCINOGENESIS
Gènes
Survival
MORTALITY
Eligibility
Cancer
Genes
Gene methylation
Immunosuppressant
Monitoring
Venous thromboembolism
Epigenetics
Dysbiosis
Small molecules
PCR
IBD
Colorectal cancer Colibactin and lipids
Rituximab plus chlorambucil
Drug
Colorectal cancer
Patient-reported outcome
RISK
Inhibitor
Over 80s
Eradication
Algorithm
IL23
DNA methylation
Upper gastrointestinal tract
Dysbiose
Clinical guidelines
Stricture
Alkylating agents
Biologics
Methylation
Inflammatory bowel diseases
Inflammatory Bowel Diseases
18 FDG-PET/CT
Résistance
T1118 translocation
Inflammatory bowel disease
Anti-TNF
Acceptability
HIV
Ulcerative colitis
Colon cancer
Disease Progression
Endoscopic treatment
Microbiote
Crohn's disease
Resistance
Vedolizumab
Therapeutics
Colon
Colectomy
Intestinal crypts
Ustekinumab
Effectiveness
Inclusion
Helicobacter pylori
Fecal microbiota
Neoadjuvant chemotherapy
IL12
Thérapie ciblée
Gene expression
Anti-TNF agents
Consensus
Méthylation
Original Article Clinical
Immune cells
Disability
Heart disease risk factors
Surgery
Tailored therapy
MICROBIOTA
Bacteria
Tuberculosis
Cell adhesion
Contraindication
DNA METHYLATION
Cost effectiveness
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|